Interview with Cristina Garlasu, General Manager, Dr. Reddy's Laboratories…
You have been the first employee to start Dr. Reddy’s in Romania and when we look back at those early years, we see that a portfolio of gastroenterology and analgesics…
Address: Str. Polona, nr. 68 – 72, etaj 3, sector 1, Bucuresti 010505
Tel: +40 21-412.00.17
Web: http://www.egis.ro/
As EGIS Group, we are present with our products in more than 60 countries worldwide and the share of our export revenue in our total sales has been steadily growing, having reached 73% in the 2009/2010 financial year. Our extensive foreign market infrastructure is the guarantee for further growth and international success. Currently we have commercial offices and trading companies in 18 countries. In our strategic markets (Russia, other CIS-countries and Central Eastern Europe) sales is supported by a well-established marketing and distribution network, whereas in our Western and third world markets we work together with local partners.
EGIS Pharmaceuticals PLC is one of the leading pharmaceutical companies in Central Europe. Our most important activities are the production of pharmaceuticals and active pharmaceutical ingredients, pharmaceutical research and development, sales of finished products and active pharmaceutical ingredients.
Out of our three production facilities, two are in Budapest. One of them is seated in our headquarters, in Keresztúri Street, where Active Pharmaceutical Ingredients are made, and the other is in Bökényföldi Street, with our tablet, injection and packaging plants as well as commercial warehouses.
In our third facility, in Körmend, tablets, ointments, suppositories, solutions, syrups and aerosols are made and packaged.
Our production system meets the international GMP principles and the regulations of the Hungarian National Institute of Pharmacy.
Production of Active Pharmaceutical Ingredients
Production of active pharmaceutical ingredients is an important field in the activity of EGIS PLC (and its legal predecessors). As a result of professional experience accumulated through the efforts of the last decades and the continuous modernization of the facilities, competitiveness of the production of active pharmaceutical ingredients has been maintained as it is well proved by successful exports and the good results of the national and international official controls.
At present, in this field of activity approximately 50 different active pharmaceutical ingredients and their intermediates are produced a year. The wide scale of products can be characterized by the gradual renewal and replacement of individual products.
Production of active pharmaceutical ingredients has been able to respond to the challenges of quality assurance and environment protection of the recent past successfully. Thorough grounding and commitment of people working in this strategic field are an important part of the complex professional culture belonging to EGIS.
Pharmaceutical Research and Development
Our research activity is aimed at the development of generic pharmaceutical products offering high marketing potential, the chemical synthesis of putative original drug molecules, and testing of their pharmacological effects. Our research work focuses on drugs effective on cardiovascular diseases, disorders of the central nervous system, the respiratory and digestive systems. At the end of our business year, closed on 30th September 2010, the number of our registrations and marketing authorizations totalled up to 2400.
Sales of Finished Products and Active Pharmaceutical Ingredients
EGIS PLC is ranked third on the basis of the number of packages sold in the Hungarian market, and is placed fifth concerning our sales revenue.
73% of our sales revenue comes from our export activity. We export our finished products first of all to the Eastern regions like Russia, Central- and Eastern-European countries, and the CIS countries. As for the Western countries France and the UK are among our main markets for finished products, while France, the Netherlands, Japan and the United States are considered as the greatest markets for our active ingredients and intermediate export.
You have been the first employee to start Dr. Reddy’s in Romania and when we look back at those early years, we see that a portfolio of gastroenterology and analgesics…
You have just arrived as general manager in January 2011. Coming to a new market obviously means a new context, different challenges and so on. Can you first elaborate on…
You have only just arrived from Korea to head the Romanian operations at MSD. Just recently, you told in an interview with Medica Academica that MSD Romania enjoys a good…
You have been the first employee to start Dr. Reddy’s in Romania and when we look back at those early years, we see that a portfolio of gastroenterology and analgesics…
Apart from MNCs, there are many local businesses that are rather strong in the Romanian pharmaceutical market. Could you give our readers an idea of their main strengths? There is…
With a history dating back to 1668, Merck is obviously well established as the oldest pharmaceutical and chemical company in the world. Of course, we are interested in knowing how…
APMGR is obviously a rather young association that has only really been active since about a year now. Can you first comment on the timing that the Association was called…
While, today, you are in charge of voicing the concerns of the innovators in the country, let us first take a step back and see what attracted these companies to…
In order to provide our readers with a general idea of the current state of the Romanian pharmaceutical and healthcare sectors, can you first of all elaborate on the key…
Increasing integration with the world economy and accession to the European Union (EU) in 2007 have been key pillars in taking the growth potential of Romania’s pharmaceutical market to greater…
You have been general manager of this affiliate for three years after a previous tenure as general manager of Leo Pharma here and in Bulgaria. The end of 2008 through…
A lot of the opportunities and challenges in the pharma and healthcare sector of Romania depend on the overall Romanian business environment in the first place. How would you assess…
See our Cookie Privacy Policy Here